top of page
AI pixabay huge.jpg

Lingering Questions Regarding PDT Coverage

As the field of prescription digital therapeutics (PDTs) continues to evolve, many payors are still cautious, a panel of experts said at Asembia’s AXS23 Summit, in Las Vegas.


“There’s not a broad groundswell for adding coverage of PDTs,” said Diane Giaquinta, PharmD, the vice president for market access research with Ashfield Engage. “No one is championing it … so it’s falling down to what payors, PBMs [pharmacy benefit managers], and national and regional health plans think, and they are slowly evaluating.”





Commentaires


bottom of page